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%xoplasma gondii can cause severe life-threatening 
infections in immunocompromised patients. Involve- 
ment of lung or central nervous system occurs alone or 
in association with dissemination of the parasite to 
other body parts [I]. Acute infection often results 
h m  the reactivation of dormant T gondii bradyzoites 
contained within cysts after a primary infection, and 
serum antibodies may be unreliable in differentiating 
between active and chronic infection. To overcome 
this difficulty, detection of T. gondii DNA by PCR 
has been applied to blood, bronchoalveolar lavage and 
cerebrospinal fluid samples [2,3]. We report a case 
of active toxoplasmosis that was diagnosed by PCR 
analysis of the ascitic fluid in a patient treated with 
pyrime thamine. 
In September 1995, a 50-year-old man with 
idopathic myelofibrosis and evidence of past T gondii 
infection (serum IgG antibody titer at 50 I U / d  with 
no specific IgM) presented a serologic toxoplasmic 
reactivation with a 20-fold increase in anti-?: gondii 
IgG and appearance of specific IgA (index = 20, 
Platelia Sanofi Diagnostic Pasteur) without any clinical 
evidence of disease. Upon treatment with pyri- 
methamine (100 mg/day) and sulfadiazine (4 g/day), 
IgG antibodies returned to their initial values and IgA 
disappeared. Sulfadiazine was thus discontinued after 6 
weeks of treatment, and the patient was maintained on 
pyrimethamine (100 mg/day until June 1996 and then 
50 mg/day) as secondary prophylaxis. In September 
1996, the patient was admitted with significant spleno- 
megaly and ascites. Osteomedullary biopsy showed 
diffuse myelofibrosis without signs of blast crisis. A 
splenectomy was performed. Pathologic examination 
of the spleen revealed acute leukemic transformation 
and local infarction. A few days after splenectomy, 
the patient presented with fever and relapse of the 
ascites. Analysis of the peritoneal fluid showed a total 
protein content of 39 g/L, a leukocytosis of 1.8 x 106/L 
(granulocyte neutrophils 77%; macrophages, 23%), and 
rare peritoneal cells. No malignant cells were observed. 
Peritoneal cultures were negative for bacteria, f h g i  
and viruses. Toxoplasmic serologic values remained 
unchanged. T gondii DNA was detected in the ascitic 
fluid by PCR-ELISA (Boehringer Mannheim), using a 
technique that targets the B1 gene of T gondii and 
includes dUTP and uracyl DNA glycosylase to prevent 
carryover contaminations, as well as a positive internal 
control to avoid false negative results due to PCR 
inhibitors [4]. Subsequent PCR analysis of the spleen 
parenchyma that had been frozen at -8OOC after 
splenectomy was also positive for Tgondii. The patient's 
clinical status improved when therapy with sulfadiazine 
(4 g/day) and pyrimethamine (100 &day) was initiated. 
His condition remained stable and he was treated as 
an outpatient with sulfadiazine, pyrimethamine and 
hydroxycarbamide (1 g/day) . 
Serologic screening for anti-T gondii antibodies is 
part of the regular follow-up scheme for immuno- 
compromised patients at our institution. Since the 
appearance of specific IgA may occur prior to clinical 
infection in immunocompromised patients [5], and 
given the IgA index of the sample (20 is the maximurn 
value with the Platelia Sanofi Diagnostic Pasteur assay), 
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the patient was initially treated for toxoplasmosis based 
on serologic data. During the second toxoplasrmc 
episode, it is unclear whether toxoplasmic reactivation 
was initiated by the surgical procedure or had already 
started before surgery. The patient was receiving broad- 
spectrum antibacterial therapy at the time of sampling 
of the peritoneal fluid. Therefore, negative culture for 
bacteria cannot rule out the possibility of a bacterial 
peritonitis, although the cell count of the peritoneal 
fluid makes this hypothesis unlikely. Whilst detection 
of DNA by PCR is not absolute evidence for the 
presence of viable 7: gondii, rapid clinical improvement 
with resolution of the fever after institution of specific 
antiprotozoal therapy supports the diagnosis of active 
toxoplasmosis. The fact that the patient was treated 
with pyrimethamine at the time of reactivation 
confirms previous reports that pyrimethamine alone 
is not always efficient in preventing toxoplasmosis 
in immunocompromised patients [6],  and further 
emphasizes the importance of DNA amplification, 
since diagnosis of toxoplasmosis is unlikely to be 
established by mice inoculation or cell culture in a 
patient receiving antiprotozoal therapy. 
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Meningococcal hsease remains an important public- 
health problem in both developing [l] and industrial- 
ized countries [2]. Before 1990, the annual incidence 
of meningococcal dlsease in Belgium fluctuated around 
one case per 100000 inhabitants. However, since the 
early 1990s an increase in the incidence of meningo- 
coccal hsease has been seen. 
Meningococci are subdivided into serotypes based 
on the immunologic properties of several outer- 
membrane proteins and lipopolysaccharides (31, and 
development of monoclonal antibodies against those 
antigens has significantly contributed to a better under- 
standing of the epidemiology of meningococcal disease 
In Belgium, serogroup B is the predominant sero- 
group causing meningococcal dlsease, followed by 
serogroup C. No effective vaccine is currently avail- 
able for protection against group B meningococcal 
disease, because the B capsular polysaccharide is not 
immunogenic in humans [4]. The recent emergence of 
penicillin-resistant meningococcal strains [5,6] may 
create additional therapeutic problems. 
In the present investigation we describe the 
spread in Belgium of a serogroup B strain which 
was first reported in The Netherlands in the early 
1980s [7]. Isolates were characterized by traditional 
serotyping, and their susceptibility patterns to a panel 
of antimicrobial agents were determined. Extensive 
phenotyping (multilocus enzyme electrophoresis) and 
genotyping (PCR and pulsed-field gel electrophoresis 
analyses) were performed on these and other strains [8] .  
Meningococcal infections are notifiable in Belgium. 
Trends of meningococcal disease have been derived 
from epidemiologic and laboratory data sets that are 
complementary but are maintained separately. On the 
one hand, the Federal Belgian Health Inspection 
receives physician notifications; data include age, 
gender, date and location. On the other hand, the 
Belgian Meningococcal Reference Center at the 
Scientific Institute for Public Health-Louis Pasteur 
(Brussels) receives isolates of Neisseria meningitidis horn 
[31. 
